Poland develops reimbursement of expensive treatments
This article was originally published in Scrip
Executive Summary
Poland's national health insurance fund (NFZ) will continue to reimburse expensive therapies, which have not been included into the health ministry's reimbursement list and which have little chance of inclusion, under special programmes. Out-patient clinics will run an increasing number of these programmes to improve the availability of treatments to patients.
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.